This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Joseph Moisseiev, MD; Amir Alhalel, MD; Ronen Masuri, MD; Giora Treister, MD

Arch Ophthalmol. 1995;113(2):185-189.

Abstract
Objective
To determine the percent of cases with all primary forms of exudative age-related macular degeneration that are eligible for treatment by the Macular Photocoagulation Study (MPS) guidelines in a retina clinic serving both as a primary care center and as a referral center.

Design
Fluorescein angiograms of patients with age-related macular degeneration examined at the Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel, during a 5-year period (1985 to 1990) were randomly selected and reviewed. Angiograms showing all forms of exudative age-related macular degeneration were eligible. The first 100 eligible angiograms identified constituted the study series and were classified into four groups: active choroidal neovascularization (CNV), pigment epithelium detachment, hemorrhage, and disciform scars. The active CNVs were further divided into three subgroups: classic (well defined), occult (poorly defined), and combined. Eligibility for laser treatment was determined exclusively with use of the published MPS recommendations for treatment of extrafoveal, juxtafoveal, and subfoveal membranes.

Results
There were 10 cases in the pigment epithelium detachment group, 11 cases in the hemorrhagic group, and 16 cases with disciform scars. All of these 37 cases were ineligible for treatment by MPS guidelines. Sixty-three eyes had active membranes; 37 were classic CNVs (eight extrafoveal, seven juxtafoveal, and 22 subfoveal). All extrafoveal and juxtafoveal CNVs were found to be eligible for laser treatment. Eleven membranes of the subfoveal group were larger than 2 disc areas, a size for which the MPS did not demonstrate benefit from laser treatment. There were 19 membranes in the strictly occult CNV subgroup, all of them untreatable by MPS criteria. Seven cases had both occult and classic CNV, and all were larger than 3.5 disc areas and therefore ineligible for treatment. Overall, 26 cases were eligible for treatment by strict MPS criteria; these constitute 26% of the whole series and 41% of the active CNV cases in the series.

Conclusions
Our results indicate that the MPS guidelines for laser treatment are applicable only to a minority of the cases with exudative age-related macular degeneration presenting to our clinic. Further studies should be conducted to identify additional treatment modalities for this common eye disease.

Author Affiliations
From the Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel, and the Sackler School of Medicine, Tel Aviv (Israel) University.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration
Cohen et al.
Br J Ophthalmol 2007;91:1173-1176.
ABSTRACT | FULL TEXT  

Estimating the yearly number of eyes with treatable neovascular age-related macular degeneration using a direct standardization method and a markov model.
Korobelnik et al.
IOVS 2006;47:4270-4276.
ABSTRACT | FULL TEXT  

Lesion morphology in age-related macular degeneration and its therapeutic significance.
Beaumont and Kang
Arch Ophthalmol 2006;124:807-812.
ABSTRACT | FULL TEXT  

Reengineering of Aged Bruch's Membrane to Enhance Retinal Pigment Epithelium Repopulation
Tezel et al.
IOVS 2004;45:3337-3348.
ABSTRACT | FULL TEXT  

Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration
Hopley et al.
Br J Ophthalmol 2004;88:982-987.
ABSTRACT | FULL TEXT  

Photodynamic Therapy With Verteporfin for Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration: Results of an Effectiveness Study
Sharma et al.
Arch Ophthalmol 2004;122:853-856.
ABSTRACT | FULL TEXT  

Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants
Hopley et al.
Br J Ophthalmol 2004;88:450-454.
ABSTRACT | FULL TEXT  

Inhibition of Choroidal Neovascularization in Rats by the Urokinase-Derived Peptide A6
Koh et al.
IOVS 2004;45:635-640.
ABSTRACT | FULL TEXT  

Relationship between Refraction and Prevalent as well as Incident Age-Related Maculopathy: The Rotterdam Study
Ikram et al.
IOVS 2003;44:3778-3782.
ABSTRACT | FULL TEXT  

Retinal Pigment Epithelium Wound Healing in Human Bruch's Membrane Explants
Wang et al.
IOVS 2003;44:2199-2210.
ABSTRACT | FULL TEXT  

A Randomized Clinical Trial of a Single Dose of Intravitreal Triamcinolone Acetonide for Neovascular Age-Related Macular Degeneration: One-Year Results
Gillies et al.
Arch Ophthalmol 2003;121:667-673.
ABSTRACT | FULL TEXT  

Age related macular degeneration
Chopdar et al.
BMJ 2003;326:485-488.
FULL TEXT  

Eligibility for treatment and angiographic features at the early stage of exudative age related macular degeneration
Haddad et al.
Br J Ophthalmol 2002;86:663-669.
ABSTRACT | FULL TEXT  

Short-Term Study of Allogeneic Retinal Pigment Epithelium Transplants onto Debrided Bruch's Membrane
Wang et al.
IOVS 2001;42:2990-2999.
ABSTRACT | FULL TEXT  

Suppression of Choroidal Neovascularization by Adeno-associated Virus Vector Expressing Angiostatin
Lai et al.
IOVS 2001;42:2401-2407.
ABSTRACT | FULL TEXT  

Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy
SOUBRANE and BRESSLER
Br J Ophthalmol 2001;85:483-495.
FULL TEXT  

External Beam Irradiation of Subfoveal Choroidal Neovascularization Complicating Age-Related Macular Degeneration: One-Year Results of a Prospective, Double-Masked, Randomized Clinical Trial
Marcus et al.
Arch Ophthalmol 2001;119:171-180.
ABSTRACT | FULL TEXT  

Age related macular degeneration
Bressler and Gills
BMJ 2000;321:1425-1427.
FULL TEXT  

A Model of the Incidence and Consequences of Choroidal Neovascularization Secondary to Age-related Macular Degeneration: Comparative Effects of Current Treatment and Potential Prophylaxis on Visual Outcomes in High-Risk Patients
Lanchoney et al.
Arch Ophthalmol 1998;116:1045-1052.
ABSTRACT | FULL TEXT  

Age-related Macular Degeneration: Clinical Features in a Large Family and Linkage to Chromosome 1q
Klein et al.
Arch Ophthalmol 1998;116:1082-1088.
ABSTRACT | FULL TEXT  

Correlation between Octopus perimetry and fluorescein angiography after strontium-90 plaque brachytherapy for subfoveal exudative age related macular degeneration
Jaakkola et al.
Br J Ophthalmol 1998;82:763-768.
ABSTRACT | FULL TEXT